The Effects of MBSR on Patients With TBI and Chronic Insomnia

The Effect of Mindfulness Based Stress Reduction (MBSR) on Patients With Traumatic Brain Injury and Chronic Insomnia

To evaluate the effects of Mindfulness Based Stress Reduction (MBSR) as an adjunct to usual clinical care for treatment of stress and chronic insomnia for patients with mild to moderate traumatic brain injury (MTBI). MBSR is a standardized protocol of meditation and yoga that has been studied extensively in other populations, however the effects of MBSR have not yet been well studied in the proposed population of service members with a Traumatic Brain Injury (TBI) who are experiencing insomnia.

Study Overview

Status

Unknown

Intervention / Treatment

Detailed Description

Randomized, controlled trial with 1:1 randomization (n=50). The control group will receive the usual care for TBI through the clinical program with standard providers based on usual patient evaluation and needs. The intervention group will receive MBSR in addition to the usual care through the TBI program.

The usual care pathway will include physician visits, rehabilitation therapies (PT/OT/ST/et al), and other providers as needed based on recommendations by his or her providers. Some variability will exist, but withholding standard of care would be unethical and standardizing care would be impossible. However, providers will be asked that medications, et al that could affect sleep remain unchanged during the trial period (maximum 12 weeks), which is reasonable given that patients have a chronic injury and no emergent/acute needs based on inclusion/exclusion criteria.

Subjects in a control group will be offered complimentary MBSR after 6 month follow up visit is completed.

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Virginia
      • Fort Belvoir, Virginia, United States, 22060
        • Recruiting
        • Fort Belvoir Community Hospital
        • Contact:
        • Principal Investigator:
          • John K Werner, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients with mild-to-moderate TBI (as defined by the DoD criteria)
  2. Right-handedness
  3. Insomnia Severity Index ≥15
  4. DEERS eligible at the time of enrollment
  5. Not pregnant
  6. Male and female subjects 18 to 60 years old
  7. Insomnia disorder per DSM-V criteria

Exclusion Criteria:

  1. Inability to speak or understand English (because this is a group intervention, it requires a common language)
  2. Patients who require assistance with activities of daily living (ADLs)
  3. Active practice of meditation and/or yoga or participation in meditation/yoga classes in the last 6 months prior to enrollment
  4. Signs or symptoms of upper motor neuron syndrome, any major systemic illness or unstable condition which could interfere with protocol compliance
  5. Active psychiatric disease that would interfere with participation in the trial, psychotic features, agitation, or behavioral problems within the last 3 months that could interfere with protocol compliance
  6. A history of alcohol/substance abuse or dependence within the past 6 months
  7. Any neurosurgical intervention affecting brain parenchyma
  8. Unstable seizure activity
  9. Concurrent participation in another clinical research trial with investigational drug or previous participation with the last investigational drug administered less than 4 weeks prior to screening
  10. Females who are pregnant or planning to become pregnant in 6 months following screening.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: MBSR treatment
MBSR will be administered over 8 week period.
Mindfulness Based Stress Reduction
NO_INTERVENTION: Control group
Usual care will continue for this group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Decrease in total score of Insomnia Severity Index (ISI) scale.
Time Frame: Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
compare change in Insomnia Severity Index (ISI, score range 0-28) scores at baseline, 2 week follow up and 6 month follow up. ISI measures severity of insomnia and calculated by adding the scores for all seven items. Results interpretation: 0-7 = No clinically significant insomnia; 8-14 = Subthreshold insomnia; 15-21 = Clinical insomnia (moderate severity); 22-28 = Clinical insomnia (severe). A 6 point decrease is considered clinically significant improvement in symptoms of insomnia.
Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in cognitive function as measured by NIH toolbox
Time Frame: Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Compare changes in cognitive assessment measured by National Institute of Health (NIH) Toolbox between the groups and at baseline and 2 week follow up within the group.
Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Change in PCL-5 (Post Traumatic Stress Disorder Check List-5) score
Time Frame: Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Compare changes in total scores in PTSD Check List-5 (PCL-5) (range 0-80) scores between the groups at baseline, 2 week follow up and 6 month follow and within the group at time points indicated. PCL-5 measures symptoms of PTSD (post traumatic stress disorder) for initial provisional diagnosis, to monitor symptoms before and after treatment and screening individuals for PTSD so they can be appropriately followed by the clinicians. A total symptom severity score (range - 0-80) can be obtained by summing the scores for each of the 20 items. symptom cluster severity scores can be obtained by summing the scores for the items within a given cluster. A provisional PTSD diagnosis can be made by treating each item rated as 2 = "Moderately" or higher as a symptom endorsed, then following the diagnostic rule which requires at least: 1 B item (questions 1-5), 1 C item (questions 6-7), 2 D item
Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Change in RAND-36 (RAND corporation 36 item Health Survey) score
Time Frame: Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Compare changes in total scores in RAND corporation 36 item Health Survey (RAND-36 range 0-100 on each item) between the groups at baseline, 2 week follow up and 6 month follow and within the group at time points indicated. RAND-36 measures eight concepts: physical functioning, bodily pain, limitations due to physical health problems, limitations due to emotional or personal problems, emotional well-being, social functioning, energy/fatigue and general health perceptions. It also includes a single item that provides an indication of perceived change in health.Scoring the RAND 36-Item Health Survey is a two-step process. First, precoded numeric values are recoded per the scoring key given in Table 1. Note that all items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible score achieved. In
Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Change in PHQ-9 (Patient Health Questionnaire 9) score
Time Frame: Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Compare changes in total scores in Patient Health Questionnaire 9 (PHQ-9, score range 0-27) between the groups at baseline, 2 week follow up and 6 month follow and within the group at time points indicated. PHQ-9 assesses depression. Scoring: add up all checked boxes on PHQ-9 For every checked Not at all = 0; Several days = 1;More than half the days = 2; Nearly every day = 3, Interpretation of Total (sum of all items) Score: 1-4 Minimal depression; 5-9 Mild depression; 10-14 Moderate depression; 15-19 Moderately severe depression; 20-27 Severe depression
Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Change in FSS (Fatigue Severity Scale score)
Time Frame: Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Compare changes in total scores in Fatigue Severity Scale (FSS, score range 9-63) between the groups at baseline, 2 week follow up and 6 month follow and within the group at time points indicated. The Fatigue Severity Scale (FSS) is a method of evaluating the impact of fatigue on participant. The FSS is a short questionnaire that requires participant to rate their level of fatigue. The FSS questionnaire contains nine statements that rate the severity of participant's fatigue symptoms.A total score of less than 36 suggests that participant may not be suffering from fatigue. A total score of 36 or more suggests that participant may need further evaluation by a physician.
Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Change in MAAS (Mindful Attention Awareness Scale score)
Time Frame: Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Compare changes in total scores in Mindful Attention Awareness Scale (MAAS, score range 15-90) between the groups at baseline, 2 week follow up and 6 month follow and within the group at time points indicated. The trait MAAS is a 15-item scale designed to assess a core characteristic of mindfulness, namely, a receptive state of mind in which attention, informed by a sensitive awareness of what is occurring in the present, simply observes what is taking place. This is in contrast to the conceptually driven mode of processing, in which events and experiences are filtered through cognitive appraisals, evaluations, memories, beliefs, and other forms of cognitive manipulation.To score the scale, simply compute a mean (average) of the 15 items. Higher scores reflect higher levels of dispositional mindfulness.
Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Change in PSS (Perceived Stress Scale)
Time Frame: Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Compare changes in total scores Perceived Stress Scale (PSS, score range 0-40) between the groups at baseline, 2 week follow up and 6 month follow and within the group at time points indicated. The PSS is a global assessment of an individual's perception of psychological stress during the past month. scores are obtained by reversing the scores on the four positive items, e.g., 0=4, 1=3, 2=2, etc. and then summing across all 10 items. Items 4,5, 7, and 8 are the positively stated items.Scores ranging from 0-13 would be considered low stress. Scores ranging from 14-26 would be considered moderate stress. Scores ranging from 27-40 would be considered high perceived stress.
Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Change in NSI (Neurobehavioral Symptom Inventory scale) score
Time Frame: Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Compare changes in total scores in Neurobehavioral Symptom Inventory (NSI, range 0-88) between the groups at baseline, 2 week follow up and 6 month follow and within the group at time points indicated. The NSI is widely used in the Department of Defense (DoD) for the evaluation of post-concussive symptoms in service members (SMs). In addition, the Department of Veterans Affairs (VA) uses the NSI in its comprehensive traumatic brain injury (TBI) evaluation. Scores are summed at initial visit and follow up visit. number of symptoms of moderate, severe, and very severe intensity and a list of the specific symptoms in each of these rating categories. Change in individual symptom scores of two or more points in a positive direction consistent with recovery (i.e. very severe to moderate, mild or none; severe to mild or none; moderate to none). Change in individual symptom scores of two or more points indicative of symptom worsening or deterioration.
Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Any changes in blood biomarkers
Time Frame: Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Compare any changes in biomarkers - cytokines (il-6, IL-10, TNFa), tau, BDNF, IGF-1, amyloid beta 40/42, and melatonin measured at pg/ml at baseline and 2 week follow up.
Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
Changes in SE- sleep efficiency measured by actigraphy devices and polysomnography.
Time Frame: Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion
to compare sleep sleep efficiency in % as calculated by total time asleep/total sleep time determined by actigraphy devices and polysomnography.
Change in the score at baseline, 2 week follow up post treatment completion, 6 months follow up post treatment completion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 12, 2018

Primary Completion (ANTICIPATED)

June 1, 2019

Study Completion (ANTICIPATED)

September 1, 2019

Study Registration Dates

First Submitted

March 13, 2018

First Submitted That Met QC Criteria

June 15, 2018

First Posted (ACTUAL)

June 18, 2018

Study Record Updates

Last Update Posted (ACTUAL)

June 18, 2018

Last Update Submitted That Met QC Criteria

June 15, 2018

Last Verified

June 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on TBI (Traumatic Brain Injury)

Clinical Trials on MBSR

3
Subscribe